Ocular Therapeutix (OCUL) EBT (2013 - 2026)
Ocular Therapeutix's quarterly EBT came in at -$90.1 million in Q1 2026, down 42.79% year-on-year from -$157.4 million in Q1 2025, and down 38.04% quarter-over-quarter from -$65.2 million in Q4 2025.
Ocular Therapeutix has reported EBT for 14 years, with the latest figure at -$90.1 million in Q1 2026.
- For the quarter ending Q1 2026, EBT fell 42.79% year-over-year to -$90.1 million; the trailing twelve-month figure through Mar 2026 stood at -$290.5 million (down 47.9% YoY), and the FY2025 full-year result was -$263.5 million, down 59.62% from the prior year.
- EBT for Q1 2026 stood at -$90.1 million, down from -$65.2 million in the prior quarter.
- The five-year high for EBT was -$19.5 million in Q1 2022, with the low at -$90.1 million in Q1 2026.
- Average EBT over 5 years is -$40.8 million, with a median of -$31.7 million recorded in 2024.
- Year-over-year, EBT rose 10.95% in 2022 and plunged 115.51% in 2024.
- Tracing OCUL's EBT over 5 years: stood at -$20.8 million in 2022, then retreated by 9.42% to -$22.7 million in 2023, then sank by 115.51% to -$49.0 million in 2024, then tumbled by 33.13% to -$65.2 million in 2025, then slumped by 38.04% to -$90.1 million in 2026.
- The last three EBT figures came in at -$90.1 million (Q1 2026), -$65.2 million (Q4 2025), and -$68.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | -90.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -90.07 Mn |
| Dec 31, 2025 | -65.25 Mn |
| Sep 30, 2025 | -67.97 Mn |
| Jun 30, 2025 | -67.20 Mn |
| Mar 31, 2025 | -63.08 Mn |
| Dec 31, 2024 | -49.01 Mn |
| Sep 30, 2024 | -43.57 Mn |
| Jun 30, 2024 | -40.75 Mn |
| Mar 31, 2024 | -31.75 Mn |
| Dec 31, 2023 | -22.74 Mn |
| Sep 30, 2023 | -21.43 Mn |
| Jun 30, 2023 | -21.81 Mn |
| Mar 31, 2023 | -23.75 Mn |
| Dec 31, 2022 | -20.79 Mn |
| Sep 30, 2022 | -23.06 Mn |
| Jun 30, 2022 | -21.54 Mn |
| Mar 31, 2022 | -19.50 Mn |
| Dec 31, 2021 | -19.72 Mn |
| Sep 30, 2021 | -21.18 Mn |
| Jun 30, 2021 | -21.88 Mn |
| Mar 31, 2021 | -21.90 Mn |
| Dec 31, 2020 | -16.06 Mn |
| Sep 30, 2020 | -15.72 Mn |
| Jun 30, 2020 | -19.56 Mn |
| Mar 31, 2020 | -18.11 Mn |
| Dec 31, 2019 | -22.99 Mn |
| Sep 30, 2019 | -24.49 Mn |
| Jun 30, 2019 | -22.85 Mn |
| Mar 31, 2019 | -20.35 Mn |
| Dec 31, 2018 | -17.40 Mn |
| Sep 30, 2018 | -15.01 Mn |
| Jun 30, 2018 | -13.80 Mn |
| Mar 31, 2018 | -13.77 Mn |
| Dec 31, 2017 | -13.10 Mn |
| Sep 30, 2017 | -15.57 Mn |
| Jun 30, 2017 | -18.69 Mn |
| Mar 31, 2017 | -16.02 Mn |
| Dec 31, 2016 | -12.82 Mn |
| Sep 30, 2016 | -9.60 Mn |
| Jun 30, 2016 | -11.45 Mn |
| Mar 31, 2016 | -10.84 Mn |
| Dec 31, 2015 | -10.64 Mn |
| Sep 30, 2015 | -11.53 Mn |
| Jun 30, 2015 | -10.01 Mn |
| Mar 31, 2015 | -7.58 Mn |
| Dec 31, 2014 | -7.95 Mn |
| Sep 30, 2014 | -7.18 Mn |
| Jun 30, 2014 | -6.20 Mn |
| Mar 31, 2014 | -6.87 Mn |
| Dec 31, 2013 | -3.51 Mn |
| Sep 30, 2013 | -3.53 Mn |
| Jun 30, 2013 | -3.09 Mn |